# US 2010/0063059 A1 · Novel pyridazine compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063059 A1
- Document ID: US20100063059A1
- Status: Published application
- Kind: A1
- Application number: 12/303,207
- Filed: 2007-07-06
- Published: 2010-03-11
- Earliest claimed: 2006-07-07
- Assignees: Gerhard Puerstinger; Gilead Sciences, Inc.; K. U. Leuven Research & Development
- Inventors: Steven S. Bondy; Terrence C. Dahl; David A. Oare; Reza Oliyai; Winston C. Tse; Vahid Zia
- Web page: https://patentgrep.com/patent/US20100063059A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.

## Claims

### Claim 1

A method for making a compound of formula (1)
comprising (a) reacting 5-[6-chloro-pyridazin-3-ylmethyl]-2-(2-fluoro-phenyl)-5H-imidazo[4,5-c]pyridine with 2,4-bis(trifluromethyl)phenylboronic acid in the presence of a solvent having the structure R1OR2O(R4O)aR3 wherein each of R1, R2, R3 and R4 are independently selected from C1-C6 alkyl and a is 0 or 1, and (b) recovering compound (1).

### Claim 2 (depends on 1)

The method of claim 1 wherein a is 0.

### Claim 3 (depends on 2)

The method of claim 2 wherein the solvent is dimethoxyethane.

### Claim 4 (depends on 1)

The method of claim 1 wherein a is 1.

### Claim 5

A compound having the formula (1)
and the salts and solvates thereof.

### Claim 6 (depends on 5)

The compound of claim 5 as the free base.

### Claim 7 (depends on 5)

The compound of claim 5 which has been micronized.

### Claim 8 (depends on 5)

The compound of claim 5 as a suspension.

### Claim 9 (depends on 5)

The suspension of claim 5 in an aqueous medium.

### Claim 10 (depends on 5)

The compound of claim 5 as a solution.

### Claim 11 (depends on 10)

The compound of claim 10 in solution with a C4-C22 fatty acid.

### Claim 12 (depends on 11)

The solution of claim 11 wherein the fatty acid is oleic acid or lauric acid.

### Claim 13 (depends on 5)

A composition comprising the compound of claim 5 and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the excipient is a C4-C22 fatty acid.

### Claim 15 (depends on 14)

The composition of claim 14 which is an aqueous solution and wherein the fatty acid is oleic acid.

### Claim 16 (depends on 5)

A method for therapy or prophylaxis of an HCV infection comprising administering to a subject an HCV therapeutic or prophylactic dose of the compound of claim 5.

### Claim 17 (depends on 16)

The, method of claim 16 wherein the subject is a human.

### Claim 18 (depends on 17)

The method of claim 17 further comprising administering to the subject a therapeutically effective dose of another agent for the treatment or prophylaxis of an HCV infection.

### Claim 19 (depends on 18)

The method of claim 18 wherein the agent, is an interferon.

### Claim 20 (depends on 17)

The method of claim 17 wherein the therapeutically effective dose is about from 0.5-5.0 mg/kg BID.

### Claim 21 (depends on 20)

The method of claim 20 wherein the dose is about from 0.7-2.2 mg/kg BID.

### Claim 22 (depends on 5)

The compound of claim 5 for use as a medicine.

### Claim 23 (depends on 5)

The use of the compound of claim 5 for the manufacture of a medicament for the prevention or treatment of an HCV infection in a mammal.

### Claim 24 (depends on 23)

The use of claim 23 wherein the viral infection is an infection with HCV.

### Claim 25 (depends on 23)

The use of claim 23 wherein the mammal is a human.

### Claim 26

A method for the preparation of compound (1) comprising providing the intermediate (2)
coupling 2,4-bis(trifluoromethyl)phenylboronic acid to 3-chloro-6-methylpyridazine to produce compound (2a)
treating compound (2a) with a chlorinating agent to produce the alkylating agent (3)
and using alkylating agent (3) to alkylate intermediate (2)under basic conditions to yield compound (1)

### Claim 27

A compound of formula (3)
and its analogues substituted with methyl rather than chloromethyl, and its analogues substituted with bromo, fluro or iodo in place of chloro.
